Abstract
Tuberculosis (TB) remains one of the most severe infectious diseases. It is still of paramount importance to establish more accurate, rapid, and efficient diagnostic methods. Since infection with Mycobacterium tuberculosis (M. tb) is largely mediated through the respiratory tract, IgA responses against mycobacterial proteins are worthy of investigation for their potential clinical utility. In this study, the IgA response targeting lipoprotein Z (LppZ) was determined by using a homemade ELISA with plasma of TB patients ($N = 125$), LTBI individuals ($N = 92$), healthy controls (HCs) ($N = 165$), as well as TB patients undergoing anti-TB treatment ($N = 9$). In parallel the antigen-specific IFN-\gamma release from PBMCs triggered by LppZ and M. tb-specific ESAT-6 or CFP-10 was detected by using an ELISPOT assay. It was found that the LppZ-specific IgA level was dramatically higher in TB patients than in HCs ($p < 0.0001$). Compared to that before anti-TB treatment, the LppZ-specific IgA level decreased substantially after 2 months of anti-TB treatment ($p = 0.0297$) and remained at low levels until the end of the treatment. What is more, pulmonary TB patients exhibited significantly higher LppZ-specific IgA-values than extra-pulmonary TB patients ($p = 0.0296$). Interestingly, the LppZ-specific IgA-values were negatively correlated to the amounts of IFN-\gamma released in response to LppZ with statistical significance ($r = -0.5806, p = 0.0002$). LppZ-specific IgA level was also higher in LTBI individuals than in HCs ($p < 0.0001$). Additionally there were some PPD$^+$ HC individuals with high LppZ-specific IgA levels but the potential of this assay for identifying leaky LTBI in PPD$^+$ HCs needs to be further investigated through follow-up studies. The sensitivity of detecting TB solely with ESAT-6 or CFP-10-specific IFN-\gamma release was increased by including the LppZ-specific IgA results, respectively, from 86.11 to 100% and 88.89 to 100%; the sensitivity of screening for LTBI was increased from 80.36 to 83.93% and 57.14 to 69.64%, respectively. The higher LppZ-specific IgA responses in TB and LTBI populations than in controls indicated high immunoreactivity to LppZ upon M. tb infection. Although the assay was not efficient enough for independent application in sero-diagnosis, LppZ-specific IgA might become a complementary biomarker for the improvement of TB and LTBI screening.
Introduction
Tuberculosis remains a global health crisis, and current diagnostic tools have significant "blind spots." The "gold standard"—sputum culture—is slow and often difficult to obtain from children or patients with extra-pulmonary TB. On the other hand, blood tests like IGRAs (which measure T-cell responses) often struggle to distinguish between active disease and latent infection, or they lack the sensitivity needed for reliable screening in high-burden areas.
Because M. tuberculosis primarily enters the body through the respiratory tract, researchers hypothesized that the mucosal immune system—specifically Immunoglobulin A (IgA)—might provide a clearer signal of infection than the more commonly studied IgG antibodies. They chose to target Lipoprotein Z (LppZ), a conserved protein in the mycobacterial cell envelope known for its high immunogenicity.
Methods
The researchers developed a "homemade" Enzyme-Linked Immunosorbent Assay (ELISA) to detect LppZ-specific IgA in human plasma. To validate this against existing standards, they also performed ELISPOT assays to measure the release of Interferon-gamma (IFN-\gamma) from peripheral blood mononuclear cells (PBMCs) in response to LppZ and standard TB antigens (ESAT-6 and CFP-10).
The study utilized a cross-sectional design involving 382 subjects: 125 active TB patients, 92 LTBI individuals, 165 healthy controls (HCs), and a longitudinal group of 9 TB patients monitored during treatment.
Key Results and Insights
Diagnostic Sensitivity and Specificity
LppZ-specific IgA levels were dramatically higher in TB patients than in healthy controls ($p < 0.0001$). When used alone, standard IFN-\gamma tests for ESAT-6 or CFP-10 had sensitivities of 86.11% and 88.89%, respectively. By combining these with the LppZ-specific IgA results, the diagnostic sensitivity for active TB reached 100%. For latent infection, adding the IgA assay increased the sensitivity of ESAT-6 screening from 80.36% to 83.93% and CFP-10 screening from 57.14% to 69.64%.
Clinical Correlations
- Respiratory Specificity: Patients with pulmonary TB had significantly higher IgA levels than those with extra-pulmonary TB ($p = 0.0296$), reinforcing the idea that IgA is a specific marker for respiratory mucosal involvement.
- Treatment Monitoring: In the longitudinal group, LppZ-specific IgA levels dropped sharply after just two months of treatment ($p = 0.0297$). This suggests that IgA levels correlate with the bacillary load, potentially making it a tool for monitoring treatment response.
- Immune Response Balance: A significant negative correlation ($r = -0.5806$) was found between LppZ-specific IgA levels and LppZ-triggered IFN-\gamma$ release. This suggests a "tilt" in the immune system toward either a humoral or cellular response in different patients.
Conclusion
While LppZ-specific IgA is a strong biomarker, its specificity is not yet high enough for standalone diagnostic use. However, its ability to boost the sensitivity of existing IGRAs to 100% for active TB makes it a highly valuable complementary tool. Future work should focus on standardizing the ELISA and conducting larger longitudinal studies to confirm its utility in monitoring bacterial clearance and predicting progression in "leaky" LTBI cases.
Summary updated